NEWS BITES - EUROPE
www.buysellsignals.com
Banco Santander, S.A.'s (MA: SAN EUR3.45) stock price traded between an intraday low of EUR3.43 and a high of EUR3.51, suggesting a trading opportunity between peaks and troughs.
Banco Santander's stock price decreased 3.0c (0.9%) from its previous trading session to close at EUR3.45.
Compared with the IBEX 35 Index which fell 116.0 points (1.2%) in the day, the relative price increase was 0.4%.
Banco Santander, S.A. is Spain's largest Banks sector company by market cap.
There were 20,100,000 shares worth EUR69.3 million ($73.8 million) traded today. The volume was 0.5 times the average daily trading volume of 36.7 million shares.
BANCO SANTANDER (SAN) Stock Dashboard [traded in Euro, EUR] End-of-Day
| Exchange | SPANISH [Madrid] | 52-Week Price Range | 2.26 - 3.80 |
| Currency | 1.000 EUR = 1.065 USD | Sector | Banks company |
| Sep 25, 2023 | EUR3.45 | Market Cap | EUR59 billion [US$63 billion] |
| EPS (FY2021) | 43.80c | Shares Outstanding | 17,080,711,000 |
| DPS (past 12 months) | 12c | SAN in Indices | IBEX 35 |
| Ave Daily Volume | 36,666,769 shares | PVEUR1000 (1 yr) PVUS$1000 (1 yr) | EUR1,484 US$1,606* |
*If You Invested $1,000 in Banco Santander a year ago, This is How Much You Would Have Today: $1,606. USD1000 would have bought EUR2,381 for 419.9 shares (@the then price of 2.42) worth EUR1,484 @3.45 today. Dividends reinvested are worth $64.
INDEX
SECTION 1 RECENT NEWS AND RESEARCH
SECTION 2 TODAY'S BULLISH SIGNALS
SECTION 3 ONGOING BULLISH PARAMETERS
SECTION 4 TODAY'S BEARISH SIGNALS
SECTION 5 ONGOING BEARISH PARAMETERS
SECTION 6 CORPORATE PROFILE AND INDEPENDENT RATINGS
APPENDIX I DATA & ARCHIVE DOWNLOAD CENTER
APPENDIX II OTHER LISTINGS AND STOCK IDENTIFIERS
GLOSSARY
SECTION 1 RECENT NEWS AND RESEARCH
Press Releases and Corporate Wire
July 18: Banco Santander Sanofi: Information concerning the total number of voting rights and shares June 2023
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de lAutorite des Marches Financiers (Regulation of the French stock market authority)
Sanofia French societe anonyme with a registered share capital of 2,521,494,572 Registered office : 46, avenue de la Grande Armee - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395030844
Source: West Corporation
July 28: Banco Santander Press Release: Sanofi to acquire Qunol, a fast-growing U.S. brand in the healthy aging segment
Sanofi to acquire Qunol, a fast-growing U.S. brand in the healthy aging segment
Transaction brings Qunol, a trusted, profitable double-digit growth and market-leading brand in health & wellness to Sanofis CHC U.S. portfolioAddition of Qunols CoQ10 and Turmeric products strengthens Sanofis CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S. Paris, July 28, 2023. Sanofi announces today it has entered into a definitive agreement to acquire ownership of Qunol, a U.S.-based, market-leading brand in health & wellness. This transaction will strengthen Sanofis Consumer Healthcares (CHC) Vitamin, Mineral and Supplements (VMS) category, one of the largest and fastest-growing consumer health categories in the U.S., focusing on the active healthy aging segment. With Qunols CoQ10 in heart health and Turmeric in joint health, CHC at Sanofi adds a trusted, profitable double-digit growth brand to its U.S. portfolio, focused on chronic conditions with growing consumer demand. With this acquisition, Sanofi continues to pursue growth opportunities and value creation for its consumer healthcare business.
Julie Van OngevalleExecutive Vice President, Consumer Healthcare, SanofiThe acquisition of Qunol further strengthens our portfolio in the wellness category. It taps into the growing healthy aging segment and fills one of our white spaces in the US, unlocking an opportunity for us to build on our U.S. presence and accelerate our growth. VMS now functions as long-term support for overall health and wellness where proactive preventive health has become the new norm post-pandemic. We are excited to welcome Qunol and, with this addition to our consumer healthcare portfolio, reinforce our commitment to bring more health into the hands of people.
Qunol CoQ10 and Turmeric products are both backed by science literature and strong market positioning in their segments.
August 03: Banco Santander Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus (nirsevimab-alip) to protect infants against RSV disease
U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus (nirsevimab-alip) to protect infants against RSV disease
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee voteCommittee also voted unanimously to include Beyfortus in the Vaccines for Children program, supporting equitable access for all eligible infantsBeyfortus is the first RSV prevention approved to protect all infants in the U.S. through their first RSV season and will be available ahead of the 2023-2024 RSV season Paris, August 3, 2023. The U.S. Centers for Disease Control and Preventions (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously 10 to 0 to recommend routine use of Sanofi and AstraZenecas Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease for newborns and infants below 8 months of age born during or entering their first RSV season.
The Committee also voted unanimously 10 to 0 to recommend routine use of Beyfortus for children aged 8 to 19 months who are at increased risk of severe RSV disease and entering their second RSV season.
Additionally, the ACIP voted unanimously 11 to 0 to include Beyfortus in the Vaccines for Children (VFC) program. Beyfortuswill be available in the U.S. ahead of the upcoming 2023-2024 RSV season.
Thomas Triomphe Executive Vice President, Vaccines, Sanofi Today, we have turned the corner on the threat of RSV to our youngest, most vulnerable population. The ACIPs unanimous recommendations for routine use of Beyfortus and inclusion in the Vaccines for Children program are critical steps toward providing millions of parents in the U.S. with the ability to protect their babies through their first RSV season, when they are most susceptible to severe RSV disease.
July 28: Banco Santander Press release: Online availability of Sanofis half-year financial report for 2023
Online availability of Sanofis half-year financial report for 2023
Paris, July 28, 2023. Sanofi announces that its half-year financial report for the period ending June 30, 2023 is now available and has been filed with the French market regulator Autorite des marches financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.
This document may be found on the companys corporate website: www.sanofi.com and downloaded from the Investors page, under the heading Regulated Information in France.
July 28: Banco Santander Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
Paris, July 28, 2023
Q2 2023 sales growth of 3.3% at CER and business EPS(1) growth of 8.1% at CER
Specialty Care grew 11.8% driven by Dupixent (2,562 million, +34.2%) and Nexviazyme (103 million, +146.5%) more than offsetting anticipated impact of Aubagio generic competition in the U.S.Vaccines up 9.1% due to strong PPH vaccines sales in Rest of World region and COVID vaccine supply in EuropeGeneral Medicines core assets grew 2.4%, non-core assets lower mainly due to Lantus (353 million, -36.5%) CHC sales growth continued (+0.7%) despite unfavorable effect from inventory build in the prior quarterBusiness EPS(1) of 1.74 up 0.6% on a reported basis and 8.1% at CER IFRS EPS of 1.15 (up 22.3%) Key R&D milestones and regulatory achievements in Q2
Nirsevimab unanimous FDA AdCom vote for prevention of RSV lower respiratory tract disease in infantsDupixent BOREAS Phase 3 COPD results presented at ATS and published in the New England Journal of MedicineItepekimab in COPD passed a recent interim futility analysis of the Phase 3 AERIFY studiesAmlitelimab positive Phase 2b data support potential for transformational target profile in Atopic DermatitisFrexalimab Phase 2b primary endpoint met demonstrating significantly reduced disease activity in MSVaccines pipeline moving at pace with 12 innovative assets with new data highlighted at a recent investor event Progress on Corporate Social Responsibility strategy in Q2
Inclusivity targets implemented across clinical trial; 45% of U.S. trials achieved at least 1 targetB Corp Certification granted to CHC North America in recognition of environmental and social achievements Full-year 2023 business EPS guidance revised upward
Paul Hudson, Sanofi Chief Executive Officer, commented:
We have delivered yet another quarter of growth, with Specialty Care and Vaccines as the main drivers.
July 17: Banco Santander Press Release: FDA approves Beyfortus (nirsevimab-alip) to protect infants against RSV disease
FDA approves Beyfortus (nirsevimab-alip) to protect infants against RSV disease
Beyfortus is the first monoclonal antibody approved to protect all infants through their first RSV seasonAcross all clinical endpoints, a single dose of Beyfortus delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseApproval also includes use for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season Paris, July 17, 2023. The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZenecas Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. The companies plan to make Beyfortus available in the U.S. ahead of the upcoming 2023-2024 RSV season.
RSV is the leading cause of hospitalization for infants under the age of one in the U.S., averaging 16 times higher than the annual rate for influenza.1,2 Each year, an estimated 590,000 RSV disease cases in infants under one require medical care, including physician office, urgent care, emergency room visits and hospitalizations.3
Thomas TriompheExecutive Vice President, Vaccines, SanofiTodays approval marks an unprecedented moment for protecting infant health in the U.S., following an RSV season that took a record toll on infants, their families, and the U.S. healthcare system. Beyfortus is the only monoclonal antibody approved for passive immunization to provide safe and effective protection for all infants during their first RSV season. I am proud that, by prioritizing this potential game-changer, we are now about to bring Beyfortus to American families.
Iskra ReicExecutive Vice President, Vaccines and Immune Therapies, AstraZenecaBeyfortus represents an opportunity for a paradigm-shift in preventing serious respiratory disease due to RSV across a broad infant population in the U.S.
June 29: Banco Santander Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
Vaccines Investor EventVaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
Sustained growth in the vaccines business will be driven by core franchises of influenza, meningitis, and pediatric vaccines, with the addition of a best-in-class RSV franchise that aims to protect infants, toddlers and older adults. Sanofi has made strides in bolstering its vaccines R&D, including the rapid development of a leading-edge mRNA platform, coupled with a global footprint of industrial and commercial expertise.Thomas Triomphe Executive Vice President, Vaccines, SanofiToday, were pleased to showcase how vaccines R&D is significantly contributing to the continued growth of the company through the design, development, and delivery of vaccines that address unmet needs. The pace of our innovation is buoyed both by a sense of urgency to address existing public health needs at multiple stages in life, and by our continued transformation as a company that simply wont accept good enough.
In less than two years, Sanofi has delivered a competitive mRNA platform with improved potency and thermostability that performs with both viral and bacterial targets. Using a powerful internal and external innovation ecosystem, Sanofis mRNA Center of Excellence has accelerated the science of mRNA technology, including improved lipid nanoparticles.
Jean-Francois ToussaintGlobal Head of Vaccines R&D, SanofiWith the addition of mRNA, we now have the largest development toolbox in the industry. This allows us to tackle public health challenges like RSV across multiple stages of life, applying the right platform to the right age group. Adding machine learning and antigen design means that our future vaccines will raise the bar beyond todays high standards. With a clear focus on delivering only first- and best-in-class vaccines, were wholly focused on innovative R&D and flawless execution.
New data from 12 assets in Sanofis broad vaccines pipeline will be featured today:
Latest data from across the RSV development program, including Phase 3b HARMONIE data for Beyfortus (nirsevimab), specifically designed to protect all infants against RSV when entering their first season; positive Phase 1/2 data from the first RSV vaccine designed to protect toddlers (SP0125); and positive Phase 1/2 results from the RSV mRNA vaccine in older adults (SP0256), which lays the foundation for clinical investigation of a combination vaccine with up to three different pathogens (for example, Respiratory Syncytial Virus, human Metapneumovirus, Parainfluenza virus) for older adults.First data from the mRNA Flu Quadrivalent vaccine, and promising results of the next-generation neuraminidase-encoding mRNA Flu vaccine, supporting further development of this novel program.Latest data from the Phase 1/2 pediatric pneumococcal vaccine program (SP0202/ developed in collaboration with SK Biosciences), with positive safety and immunogenicity of the first PCV21 vaccine, designed to extend protection against disease with an innovative carrier that breaks the glass ceiling of serotype compositions.
SECTION 2 TODAY'S BULLISH SIGNALS
Banco Santander stock is the twentieth highest dividend yielding stock in the IBEX 35 Index.
2.1 Relative Value Indicators: Undervaluation compared with
Dividend Yield > 2/3rd Bond Yield:
The dividend yield of 3.41% is 0.92 times the triple-A bond yield of 3.69%; it is also above the benchmark of 2/3rd set by Benjamin Graham.
(All figures in %)
| Dividend Yield | 3.41 |
| Bond Yield | 3.69 |
| Spread | 0.28 |
2.2 Rank in the top 18% by Relative Valuation in the Spanish market
| Description | Value | Rank |
| Price to Book Value | 0.7 | In Top 18% |
2.3 Rank in the top 16% by Price Performance in the Spanish market
| Description | Value | Rank |
| PV1000 [1 yr] $ | 1,606 | In Top 16% |
2.4 Uptrend
Beta > 1 combined with price rise. The Beta of the stock is 1.6.
Price/Moving Average Price of 1.04:
- The Price/MAP 200 for Banco Santander is 1.04. Being higher than 1 is a bullish indicator. It is higher than the Price/MAP 200 for the IBEX 35 Index of 1.02, a second bullish indicator. The stock is trading above both its MAPs and the 50-day MAP of EUR3.54 is higher than the 200-day MAP of EUR3.31, a third bullish indicator.
SECTION 3 ONGOING BULLISH PARAMETERS
3.1 Rank in the top 4% by Size in the Spanish market
| Description | Value | Rank |
| Ave daily Turnover | EUR69.3 million ($73.8 million) | In Top 2% |
| MCap | $63 billion | In Top 4% |
3.2 Present Value of EUR1000 Invested in the Past [3 Mo, 1 Yr, 3 Yrs]; The Best Periods with PVEUR1000 > 1,123
| PVEUR1,000 | 3 mo ago | 1 yr ago | 3 yrs ago |
| SAN.MA | EUR1,124 | EUR1,484 | EUR4,588 |
| Banks company | EUR1,065 | EUR1,205 | EUR1,820 |
| IBEX 35 Index | EUR1,025 | EUR1,238 | EUR1,416 |
3.3 The Best Periods [3 Mo, 1 Yr, 3 Yrs] with Price Change % > 12.3
3-Year price change of 321.6% for Banco Santander outperformed the change of 41.3% in the IBEX35 Index for a relative price change of 280.3%.
| Price Change % | Quarter | Year | 3 Years |
| Banco Santander | 12.4 | 42.6 | 321.6 |
| Banks company | 6.5 | 20.5 | 81.2 |
| IBEX35 Index | -0.1 | 23.8 | 41.3 |
3.4 Created Market Value [CMV] past 3 yrs of EUR6.8 billion ($7.3 billion)
- Market Capitalization has increased by EUR32.5 billion from EUR26.4 billion to EUR58.9 billion in the last 3 years. This increase comprises cumulative retained earnings (RETE) of EUR25.7 billion and Created Market Value of EUR6.8 billion. The Created Market Value multiple, defined by the change in MCap for every EUR1 of retained earnings is EUR1.27.
3.5 Annualised Period-based Total Shareholder Returns [TSR %]: The Best Periods with TSR > 8.7%
| TSR % | 1 yr | 3 yrs | 5 yrs | 10 yrs |
| SAN.MA | 48.4 | 65.3 | 13.6 | 8.8 |
3.6 Increased VWAP, up 49% in 5 years
In the past five years Volume Weighted Average Price (VWAP) has increased by 49.2% to EUR3.12. Based on a dynamic start date of five years ago, there have been declines in VWAP in 2 out of 5 years.
Past five years, 12 months ended Sep 25 (EUR)
| Year | High Price | VWAP | Low Price |
| 2023 | 3.8 | 3.12 | 2.26 |
| 2022 | 3.28 | 2.75 | 2.23 |
| 2021 | 3.26 | 2.05 | 0.81 |
| 2020 | 2.08 | 1.37 | 0.79 |
| 2019 | 2.36 | 2.09 | 1.73 |
SECTION 4 TODAY'S BEARISH SIGNALS
4.1 Downtrend
Negative MACD:
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 3.48 minus the 26-day EMA of 3.49 is negative, suggesting a bearish signal. Both the 12-day EMA as well as the 26-day EMA are falling, another bearish signal.
Past Quarter:
The Worst 3 weeks in the past quarter
In the past quarter the steepest fall of 3.8% took place in the week beginning Monday July 03.
| Mon-Fri | Change % | IBEX35 Index Change % | Vol Ind [1 is avg] |
| Jul 03-07 | -3.8 | -3.6 | 0.6 |
| Sep 04-08 | -3.1 | -0.9 | 0.6 |
| Jul 31-Aug 04 | -1.9 | -3.3 | 0.7 |
4.2 Other Bearish Signals
- Return on Equity of 9.9% versus sector average of 11.3% and market average of 11.8%.
- Total Liabilities/EBITDA of 127.1 is more than 5, this compares unfavourably with the Joseph Piotroski benchmark of 5.
- Net profit margin has averaged 6.6% in the last 3 years. This is lower than the sector average of 18.7% and suggests a low margin of safety.
- As per the Du Pont analysis, Return on Equity of 9.9% is lower than sector average of 11.3%. This is computed as net profit margin of 20.8% times asset turnover [sales/assets] of 0.03 times leverage factor [total assets/shareholders' equity] of 16.4.
SECTION 5 ONGOING BEARISH PARAMETERS
5.1 Stock vs Index (Annual Percentage Change)
| December 31 | Last price in EUR | Annual Return | Return of IBEX 35 Index |
| 2022 | 2.8 | -1.2 | -5.7 |
| 2021 | 2.8 | 18.9 | 8.1 |
| 2020 | 2.4 | 19.6 | -15.5 |
| 2019 | 2.0 | -0.8 | 11.8 |
| 2018 | 2.0 | - | - |
Banco Santander has outperformed the IBEX 35 Index in 2 of the past 5
years: 2021, 2020.
5.2 MCap: 5-Year Decrease of EUR15 B [$15B] (20%)
In the past 5 years Market Capitalization has decreased by EUR14.5 billion (20%) from EUR73.5 billion to EUR58.9 billion. Based on a dynamic start date of 5 years ago, there have been declines in MCap in 3 out of 5 years.
| Price | MCap (EUR B) | MCap ($ B) | |
| Last | EUR3.45 | 58.9 | 62.8 |
| 1 Year ago | EUR2.42 | 43 | 41.7 |
| 2 Years ago | EUR2.78 | 49.7 | 58.3 |
| 3 Years ago | 81.83c | 25.9 | 30.5 |
| 4 Years ago | EUR1.92 | 62.5 | 69.1 |
| 5 Years ago | EUR2.23 | 73.5 | 85.8 |
5.3 Declining Volume, down 44% in 5 years
In the past five years, Average Daily Volume of Trading (ADVT) has decreased 44.1% to 36.7 million shares.
Avg. Daily Volume Traded 12 months ended Sep 25, million shares
| Year | ADVT |
| 2023 | 36.7 |
| 2022 | 37.1 |
| 2021 | 45.3 |
| 2020 | 57.2 |
| 2019 | 65.6 |
5.4 Declining share turnover, down 52% in 5 years
In the past five years, average daily share turnover has decreased 51.7% to EUR114.3 million ($121.7 million). This suggests decreased liquidity.
Past five years, 12 months ended Sep 25 (EUR million)
| Year | Average Daily Turnover |
| 2023 | 114.3 |
| 2022 | 104.4 |
| 2021 | 116.4 |
| 2020 | 140.6 |
| 2019 | 236.7 |
5.5 Satisfies 1 out of 9 criterion of Joseph Piotroski [pass mark 5]:
- Positive net income.
But does not meet the following 8 criteria of Joseph Piotroski:
- Positive operating cashflow.
- Return on Assets improvement.
- Good quality of earnings [operating cashflow exceeds net income].
- Improvement in long-term debt to total assets.
- Improvement in current ratio.
- Total shares on issue unchanged (or reduction in total shares on issue).
- Improvement in gross margin.
- Improvement in asset turnover.
SECTION 6 CORPORATE PROFILE AND INDEPENDENT RATINGS
6.1 Activities
Banco Santander SA. (the Bank) is a financial group that offers a range of financial products. It is Spain's largest Banks sector company by market capitalisation.
6.2 Independent Ratings and Relative Value Indicators
+ Newsweek 500:
Banco Santander, S.A. was ranked 157 by Newsweek and Corporate Knights Capital in the World's 500 Greenest Companies 2016. It had outstanding scores of 11.9% in Carbon productivity, 7.7% in Energy productivity and 5.9% in Water productivity.
+ S&P Global Market Intelligence 100:
Banco Santander, S.A. was ranked 18 in SNL's list of Top 100 Banks by Total Assets in 2016; an improvement over a year from rank 20 in 2015.
+ PwC 100:
It was ranked 72 by MCap as at March 31, 2015 by PwC in the Top 100 Global companies; a deterioration over 6 years from rank 65 as at March 31, 2009.
+ Brand Finance 500:
It was ranked 10 in the Brand Finance list of the world's 500 Valuable Banking brands by brand value in 2015; a deterioration over a year from rank 8 in 2014. Brand Finance valued the brand at US$18,700 million and ranked it Number 10 in Europe. Most of the brand valuation was for services such as Retail Banking.
6.3 Contact Details
| Website | http://www.gruposantander.com |
| Physical Address | Ciudad Grupo Santander Boadilla del Monte Madrid, 28660 Spain |
6.4 Industry & Sector [of 104 stocks]
| Classification Level | Name of Sector |
| Industry Group | Banking Services |
| Industry | Banks |
| Economic Sector | Financials |
| Business Sector | Banking & Investment Services |
APPENDIX I DATA & ARCHIVE DOWNLOAD CENTER
SAN: EXCEL TABLES ARE AVAILABLE TO EXPORT DATA:
+ PRICE VOLUME - 5-YEAR HISTORY
+ FINANCIALS - 10-YEAR HISTORY:
+ PEER COMPARISON - STOCK IN BANKS COMPANY SECTOR AND STOCK IN INDICES
SAN: LINKS IN HTML TO FURTHER INFORMATION:
+ NEWS ARCHIVES - SAN PAST 4 YEARS IN HTML:
+ USD vs EUR EXCHANGE RATE CHARTS IN HTML
APPENDIX II OTHER LISTINGS AND STOCK IDENTIFIERS
II.1 Primary Exchange and Other Listings: Trading Currency and Volume (Excl ADR)
| Exchange | Ticker | Currency | Last | ADVT | Vol % of Total | Today's VI |
| Madrid | SAN | EUR | 3.45 | 36,666,769 | 98.5 | 0.5 |
| London | BNC | GBX | 301.5 | 505,492 | 0.9 | 0.4 |
| Xetra | BSD2 | EUR | 3.47 | 76,096 | 0.6 | 1.5 |
| Total | 100.00 |
1 EUR= 87.0019 GBX [Pence Sterling];
ADVT= Avg. Daily Volume of Trading; VI= Volume Index (1 is avg)
II.2 Stock Identifiers
ISIN: ES0113900J37
PermID: 8589934205
CUSIP: E19790109
RIC: SAN.MC
GLOSSARY
ADVT: Average Daily Volume of shares Traded
Annual Return: Dividends Paid In a 12-Month Period/Price at the Beginning of the Period + Capital Gain or Loss over 1 Year/Price 1 Year Ago (%)
Current Ratio: Current Assets/Current Liabilities (times)
Dividend Yield: Dividend Per Share/Share Price (%)
Income during the n years (3/2/1): Dividends received during the Period
Moving Average Price (n periods): Sum of Prices for each Period/Number of Periods
PV1000: Present value of 1000 invested 1 year/'n' years ago
Price Close/Moving Avg Price: Latest Price/Moving Average Price
Price/NTA: Closing Share Price/Net Tangible Assets Per Share (times)
Relative Price Change [RPC]: Relative price change is price change of stock with respect to Benchmark Index
Return on Assets: Net Profit/Total Assets (%)
Return on Equity (Shareholders' Funds): Net Profit/Net Assets (%)
TSR: Total Shareholder Returns is expressed as an annualized rate of return for shareholders after allowing for capital appreciation and dividend
Volume Index (VI): Number of shares traded in the period/Average number of shares traded for the period
Volume Weighted Average Price (VWAP): The Volume Weighted Average Price (VWAP) is the summation of turnover divided by total volume in the same period.
Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data and analysis from Jupiter International (Australia) Pty Ltd trading as BuySellSignals (AFS Licence 222756), who provide round the clock analysis on every stock, every sector, every market, every day. BuySellSignals is not a broker, and does not have executing, corporate advisory or investment banking functions. Jupiter International (Australia) Pty Ltd, its directors, employees and contractors do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate.
Data for the BuySellSignals algorithms is drawn from annual reports, company websites and similar sources of publicly available data. It should be used as a guide only.
Created by www.buysellsignals.com